Glenmark Pharmaceuticals Limited has informed the Exchange about press release dated 11-Apr-2022 titled Glenmark Specialty S.A. receives approval for conducting Phase 1 Clinical Trial of its Novel Molecule GRC 54276 in patients with Advanced Solid Tumors and Hodgkin���s Lymphoma